Compounds > Propioveratrone
Page last updated: 2024-12-05

Propioveratrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Propioveratrone is a synthetic compound that has been studied for its potential therapeutic properties. It is a derivative of veratramine, a natural alkaloid found in the Veratrum plants. Propioveratrone has shown promising results in preclinical studies, demonstrating anti-inflammatory, analgesic, and neuroprotective effects. Its synthesis involves a multi-step process starting from veratramine. The compound's effects are attributed to its ability to modulate various signaling pathways, including the inflammatory cascade and the nervous system. The research on propioveratrone is driven by its potential to develop novel treatments for conditions like pain, inflammation, and neurodegenerative diseases. Further investigations are ongoing to understand its precise mechanisms of action and its safety profile for clinical applications.'

Cross-References

ID SourceID
PubMed CID15781
CHEMBL ID479685
CHEBI ID167438
SCHEMBL ID515746

Synonyms (38)

Synonym
nsc 16954
CHEBI:167438
1-(3,4-dimethoxy-phenyl)-propan-1-one
smr000387103
MLS001048910
1-propanone, 1-(3,4-dimethoxyphenyl)-
ai3-23454
nsc16954
3,4-dimethoxyphenyl ethyl ketone
1-(3,4-dimethoxyphenyl)-1-propanone
1835-04-7
3,4-dimethoxypropiophenone
3',4'-dimethoxypropiophenone
nsc-16954
propioveratrone
propiophenone, 3',4'-dimethoxy-
GHL.PD_MITSCHER_LEG0.580
STK043726
1-(3,4-dimethoxyphenyl)propan-1-one
AKOS000115379
CHEMBL479685
NCGC00246237-01
EN300-01082
BBL009808
1-(3,4-dimethoxyphenyl)-propan-1-one
HMS2268J04
3',4'-dimethoxy-1-phenylpropiophenone
FT-0614354
AM20030211
SCHEMBL515746
Z57952774
propan-1-one, 1-(3,4-dimethoxyphenyl)-
DTXSID60171427
mfcd00482089
1-(3,4-dimethoxy-phenyl)-propan-1-one, aldrichcpr
NS-01887
Y14672
CS-0152658
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.70790.044717.8581100.0000AID485294
glp-1 receptor, partialHomo sapiens (human)Potency7.94330.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency2.90930.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID376042Antifungal activity against Trichophyton mentagrophytes ATCC 9972 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376049Antifungal activity against Candida albicans ATCC 10231 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376052Antifungal activity against Aspergillus flavus ATCC 9170 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376043Antifungal activity against Trichophyton rubrum C 113 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376054Antifungal activity against Aspergillus niger ATCC 9029 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376055Antifungal activity against Microsporum canis C 112 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376051Antifungal activity against Cryptococcus neoformans ATCC 32264 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376044Antifungal activity against Epidermophyton floccosum C 114 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376040Antifungal activity against Microsporum canis C 112 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376053Antifungal activity against Aspergillus fumigatus ATCC 26934 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376041Antifungal activity against Microsporum gypseum C 115 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376045Antifungal activity against Microsporum gypseum C 115 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376046Antifungal activity against Trichophyton mentagrophytes ATCC by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376050Antifungal activity against Saccharomyces cerevisiae ATCC 9763 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376048Antifungal activity against Epidermophyton floccosum C 114 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376047Antifungal activity against Trichophyton rubrum C 113 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
naphthalene
[no description available]		210naphthalenes;
ortho-fused bicyclic arene		apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component
phenanthrene
phenanthrene : A polycyclic aromatic hydrocarbon composed of three fused benzene rings which takes its name from the two terms 'phenyl' and 'anthracene.'		210ortho-fused polycyclic arene;
ortho-fused tricyclic hydrocarbon;
phenanthrenes		environmental contaminant;
mouse metabolite
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		210dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
myristicin
myristicin: asaricin is an isomer; structure; a methylene dioxy version of elemicin;		210organic molecular entitymetabolite
methyleugenol
methyleugenol: structure		210phenylpropanoid
elemicin
[no description available]		210olefinic compound
isoeugenol
[no description available]		210isoeugenol
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		210antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510